Results of Operations and Financial Conditions. On August 6, 2026, TriSalus Life Sciences, Inc. (the “Company”) issued a press release announcing its financial results for the second quarter ended June 30, 2026. A copy of the press release is attached hereto as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference. This information, including Exhibit 99.1, will not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (t…

Results of Operations and Financial Conditions. On May 12, 2026 , TriSalus Life Sciences, Inc. (the “Company”) issued a press release announcing its financial results for the first quarter ended March 31, 2026. A copy of the press release is attached hereto as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference. This information, including Exhibit 99.1, will not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (th…

Chief of Clinical Operations — Jodi Devlin: Jodi Devlin is retiring from her role as Chief of Clinical Operations, with a successor already appointed.

Chief Medical Officer — Dr. Richard Marshall: The company hired a new Chief Medical Officer.

Results of Operations and Financial Conditions. On March 5, 2026, TriSalus Life Sciences, Inc. (the “Company”) issued a press release announcing its financial results for the fourth quarter and year ended December 31, 2025. A copy of the press release is attached hereto as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference. This information, including Exhibit 99.1, will not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, a…

Entry into a Material Definitive Agreement. On February 19, 2026, TriSalus Life Sciences, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Lake Street Capital Markets, LLC (“LSCM”), as representative of the underwriters named therein (the “Underwriters”), relating to the public offering (the “Offering”) of 9,756,100 shares (the “Shares”) of common stock of the Company, par value $0.0001 per share (the “Common Stock”), at a price to the public of…

Director — Dr. Arjun “JJ” Desai: Dr. Desai resigned from his position as a member of the Board.

Results of Operations and Financial Conditions. On January 12, 2026, TriSalus Life Sciences, Inc. (the “Company”) issued a press release announcing preliminary unaudited financial results for the fourth quarter and year ended December 31, 2025 and 2026 revenue guidance. A copy of the press release is attached hereto as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference. This information, including Exhibit 99.1, will not be deemed “filed” for purposes of Secti…

Results of Operations and Financial Conditions. On November 13, 2025, TriSalus Life Sciences, Inc. (the “Company”) issued a press release providing a business update and announcing its financial results for the quarter ended September 30, 2025. A copy of the press is attached hereto as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference. This information, including Exhibit 99.1, will not be deemed “filed” for purposes of Section 18 of the Securities Exchange A…

Director — Sean Murphy: Mr. Murphy resigned from his position as a member of the Board and the Science and Technology Committee.

David Patience: Compensation increase and stock options granted to the Chief Financial Officer.

of this Current Report on Form 8-K, including Exhibit 99.1, is furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information shall not be deemed incorporated by reference into any other filing with the Securities and Exchange Commission made by the Company, whether made before or after today’s date, rega…

Material Modifications to Rights of Security Holders.

Other Events. On June 23, 2025, TriSalus Life Sciences, Inc. (the “Company”), announced the commencement of (i) its exchange offer (the “Offer”) identified in the Prospectus/Offer to Exchange (as defined below) the opportunity to receive that number of shares of common stock of the Company, par value $0.0001 per share (“Common Stock”) equal to the quotient of (i) the sum of (a) the Liquidation Preference (as defined in the Certificate of Designations of the Preferred Stock (the “Certificate o…

Chief Financial Officer — James Young: Mr. James Young resigned from the Company for personal reasons.

of this Current Report on Form 8-K, including Exhibit 99.1, is furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information shall not be deemed incorporated by reference into any other filing with the Securities and Exchange Commission made by the Company, whether made before or after today’s date, rega…

Entry into a Material Definitive Agreement. Securities Purchase Agreement On April 30, 2025, TriSalus Life Sciences, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with certain institutional and accredited investors named therein (the “Purchasers”) pursuant to which the Company agreed to issue and sell to the Purchasers in a private placement (the “Private Placement”) an aggregate of 5,500,000 shares (the “Shares”) of the Company’s common stock, p…

by reference. The information in this Item 7.01, including the attached Exhibit 99.1, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing made by the Company under the Securities Act or the Exchange Act. Cautionary Statement Regarding Forward-Looking Statements Statements…

Based in part upon the representations of the Purchasers in the Purchase Agreement, the offering and sale of the Shares described above are being offered and sold in a private placement under Section 4(a)(2) of the Securities Act and Regulation D promulgated thereunder, and have not been registered under the Securities Act, or applicable state securities laws. Accordingly, such securities may not be offered or sold in the United States except pursuant to an effective registration statement or…

Results of Operations and Financial Condition. Full financial results for the quarter ended March 31, 2025 are in the process of being finalized, however initial and preliminary results show revenue, driven solely by the TriNav® Infusion System, of approximately $9.2 million in the first quarter of 2025. This represents growth of approximately 42% versus the first quarter of 2024. The preliminary results set forth above are unaudited, are based on management’s initial review of the Company’s…

Director — George Kelly Martin: Mr. Martin resigned from his positions on the Board and its committees.

Director — Liselotte Hyveled: Ms. Hyveled resigned from her position as a member of the Board and related committees.

of this Current Report on Form 8-K of this Current Report on Form 8-K, including Exhibit 99.1, is furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information shall not be deemed incorporated by reference into any other filing with the Securities and Exchange Commission made by the Company, whether made…

officer and employee — Sean Murphy: Sean Murphy is stepping down as an officer and employee of the Company.

Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. On February 18, 2025, the closing for the Second Tranche occurred and the Borrower received $10 million pursuant to the Second Tranche. The Second Tranche loan will mature on April 30, 2029. The Third Tranche remains available pursuant to the terms of the Credit Agreement. In connection with the closing of the Second Tranche and pursuant to the Credit Agreement, on February 18, 2…